About the Startup
Spanish biotechnology company developing a gene-therapy approach for Alzheimer’s disease based on a modified transcription factor (E2F4DN). Lead candidate TET-101 showed promising preclinical efficacy and safety; company is preparing a Clinical Trial Application (CTA) in Europe to move into first-in-human studies.
Frequently Asked Questions
What type of funding round did Tetraneuron raise?
Tetraneuron raised a unspecified round.
When did Tetraneuron raise its unspecified?
Tetraneuron raised its unspecified on 2025-12-09.
Who invested in Tetraneuron's unspecified?
The investors in Tetraneuron's unspecified are: Gimic Ventures.
What type of investment was Tetraneuron's unspecified?
Tetraneuron's unspecified was a equity investment.